PE20091098A1 - Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina - Google Patents
Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocainaInfo
- Publication number
- PE20091098A1 PE20091098A1 PE2008002049A PE2008002049A PE20091098A1 PE 20091098 A1 PE20091098 A1 PE 20091098A1 PE 2008002049 A PE2008002049 A PE 2008002049A PE 2008002049 A PE2008002049 A PE 2008002049A PE 20091098 A1 PE20091098 A1 PE 20091098A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclodextrin
- disulfiram
- alcohol
- useful
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/105—Persulfides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPLEJO DE INCLUSION (COMPLEJO DSF-CD´) CONSTITUIDO POR DISULFIRAM (DSF) LIBRE O NO COMPLEJADO Y CICLODEXTRINA (CD) COMO EXCIPIENTE TAL COMO HIDROXI-ß-CICLODEXTRINA. TAMBIEN SE REFIERE A UN METODO DE PREPARACION PARA UNA FORMA FARMACEUTICA DE LIBERACION MODIFICADA DE DSF PARA ADMINISTRACION ORAL Y PARENTERAL. DICHO COMPUESTO INIHIBE LA OXIDACION DEL ACELTALDEHIDO, SIENDO UTIL EN EL TRATAMIENTO DE DE LA DEPENDENCIA DE ALCOHOL Y COCAINA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL200703877A CL2007003877A1 (es) | 2007-12-28 | 2007-12-28 | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20091098A1 true PE20091098A1 (es) | 2009-08-06 |
Family
ID=40261622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008002049A PE20091098A1 (es) | 2007-12-28 | 2008-12-11 | Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina |
Country Status (10)
Country | Link |
---|---|
US (1) | US20110021458A1 (es) |
EP (1) | EP2238978A1 (es) |
KR (1) | KR101132954B1 (es) |
AR (1) | AR071553A1 (es) |
BR (1) | BRPI0821523A2 (es) |
CL (1) | CL2007003877A1 (es) |
ES (1) | ES2364419B1 (es) |
MX (1) | MX2010007183A (es) |
PE (1) | PE20091098A1 (es) |
WO (1) | WO2009083794A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2705027T3 (es) | 2010-08-19 | 2019-03-21 | Buck Institute For Age Res | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados |
EP2814491A4 (en) * | 2012-02-18 | 2015-08-26 | Buck Inst For Res On Aging | FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES |
EP3311843A1 (en) * | 2016-10-13 | 2018-04-25 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Compositions comprising dithiocarbamate and cyclodextrin |
KR20220010855A (ko) | 2020-07-20 | 2022-01-27 | 재단법인 제주테크노파크 | 디설피람 및 그 유도체를 이용한 지방세포의 분화억제 효과를 갖는 비만 개선 및 치료용 약학적 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678809A (en) * | 1985-02-01 | 1987-07-07 | Michael Phillips | Injectable fomulations of disulfiram for the treatment of alcoholism |
US5206264A (en) * | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
US5665770A (en) * | 1993-11-05 | 1997-09-09 | Gakko Hojin Kinki Daigaku | Method for treatment of cataract with radical scavenger |
KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
CN1376463A (zh) | 2002-03-29 | 2002-10-30 | 沈阳药科大学 | 双硫伦包合物滴眼剂及其制备方法 |
DK1767219T3 (da) | 2004-03-10 | 2010-05-10 | Shimoda Biotech Pty Ltd | Stabile injicerbare diclofenac-sammensætninger |
US20080004260A1 (en) * | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
-
2007
- 2007-12-28 CL CL200703877A patent/CL2007003877A1/es unknown
-
2008
- 2008-12-11 PE PE2008002049A patent/PE20091098A1/es not_active Application Discontinuation
- 2008-12-23 ES ES201090050A patent/ES2364419B1/es active Active
- 2008-12-23 AR ARP080105737A patent/AR071553A1/es not_active Application Discontinuation
- 2008-12-23 WO PCT/IB2008/003696 patent/WO2009083794A1/es not_active Application Discontinuation
- 2008-12-23 EP EP08866361A patent/EP2238978A1/en not_active Withdrawn
- 2008-12-23 US US12/811,035 patent/US20110021458A1/en not_active Abandoned
- 2008-12-23 MX MX2010007183A patent/MX2010007183A/es active IP Right Grant
- 2008-12-23 BR BRPI0821523A patent/BRPI0821523A2/pt not_active IP Right Cessation
- 2008-12-26 KR KR1020080134498A patent/KR101132954B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2238978A1 (en) | 2010-10-13 |
ES2364419A1 (es) | 2011-09-02 |
ES2364419B1 (es) | 2012-09-19 |
MX2010007183A (es) | 2010-12-17 |
BRPI0821523A2 (pt) | 2017-11-14 |
KR101132954B1 (ko) | 2012-04-24 |
US20110021458A1 (en) | 2011-01-27 |
CL2007003877A1 (es) | 2008-06-27 |
KR20090073026A (ko) | 2009-07-02 |
AR071553A1 (es) | 2010-06-30 |
WO2009083794A1 (es) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
AR050717A1 (es) | Composiciones farmaceuticas | |
UY31789A1 (es) | Composiciones de insulina de super rápida actuación | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
ECSP12012148A (es) | Composiciones sólidas | |
CO6361904A2 (es) | Composiciones de dosis orales de liberación retardad que contienen bardoloxona-metilo (cddo-me) amorfo | |
GT201000144A (es) | " composiciones farmaceuticas " | |
BR112012028291A2 (pt) | composições farmacêuticas e métodos para sua produção | |
ECSP10010106A (es) | Trans-clomifeno para el síndrome metabólico | |
AR081776A1 (es) | Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion | |
WO2009149258A3 (en) | Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
CL2012000744A1 (es) | Proceso para preparar un conjugado de polisacáridos capsulares tipo 5 o tipo 8 de s. aureus y una molécula transportadora; conjugado de polisacáridos; y composición inmunogénica que lo comprende. | |
EA201170512A1 (ru) | Композиция для перорального введения | |
DOP2009000262A (es) | Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas | |
PE20091098A1 (es) | Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina | |
BRPI0909211B8 (pt) | formulação oral em forma de comprimido de compostos de tetraciclina | |
WO2008115805A3 (en) | Cobalamin taxane bioconjugates | |
UY29307A1 (es) | Composición que comprende una epotilona y métodos para producir dicha composición | |
WO2010006392A3 (en) | Pharmaceutical composition comprising jasmonates | |
ATE533477T1 (de) | Pharmazeutische zusammensetzungen enthaltend irbesartan | |
BRPI0921286A2 (pt) | Composição imunogênica com múltiplos componentes para a prevenção de doença por estreptococos beta-hemolíticos (bhs). | |
AR068608A1 (es) | Neramexano para el tratamiento de nistagmo | |
CO6541608A2 (es) | Formulación de empaque para evitar la insolubilidad de las composiciones que contienen quitosán | |
ECSP088893A (es) | 2-alcoxi-3, 4,5-trihidroxi-alquilamida-benzazepinas, su preparación, composiciones que las contienen y utilización | |
DOP2005000274A (es) | Composicion que comprende una epotilona y metodos para producir dicha composicion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |